Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Clinical trial NCT04840602 · RECRUITING
Trial details
- NCT number
- NCT04840602
- Sponsor
- National Cancer Institute (NCI)
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-05
- Primary completion
- 2028-03-31
- Enrollment
- 92
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.